StockNews.AISignal intelligence
Mersana Therapeutics, Inc. · NASDAQ · Healthcare
Browse public MRSN signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Mersana released Phase 1 data for emiltatug ledadotin (Emi-Le). Emi-Le showed 23% objective response rate in advanced TNBC patients. FDA granted Fast Track designation for XMT-1660 in advanced breast cancer. Mersana stock decreased 36.6% to $0.8245 on the data announcement.
View signal analysis- Mersana Therapeutics quarterly loss per share was $0.16 vs. estimated $0.18. - Revenues were $9.25 million, missing estimate by 5.18%. - Stock has gained 46.6% YTD, while industry is in top 35% ranking. - Price Impact Rating: Bearish - Impact Horizon Rating: Short-term - Type: Earnings
View signal analysis